Media

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

March 28, 2019 | Publication
Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?
Davola & Mossman, OncoImmunology, 2019
March 1, 2019 | Poster
Exploratory analysis of T cell repertoire dynamics upon systemic treatment with the oncolytic virus pelareorep in combination with pembrolizumab and chemotherapy in patients with advanced pancreatic adenocarcinoma
Wilkinson Et al, AACR, 2019
January 14, 2019 | Publication
Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model
Thirukkumaram et al, Blood Advances, 2019
December 1, 2018 | Poster
Oncolytics Virus Replication Using Pelareorep and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses
Hofmeister et al, ASH, 2018
November 14, 2018 | Publication
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
LaRocca and Warner, Clinical and Translational Medicine, 2018
November 1, 2018 | Poster
Reovirus infection of prostate cancer induces upregulation of the negative regulators PD-L1 and BTLA
Pandha et al, SITC, 2018
October 1, 2018 | Poster
Dose finding and safety study of Reovirus (Reo) with irinotecan/fluorouracil/leucovorin/bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC): Final Results
Goel et al, ESMO, 2018
October 1, 2018 | Publication
Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy
Ilett et al, Cancer Immunology Research, 2018
June 15, 2018 | Publication
Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
Mostafa et al, Cancers, 2018
June 1, 2018 | Poster
A study of pelareorep in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP)
Mahalingam et al, ASCO GI, 2018
June 1, 2018 | Poster
Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy
Grey Wilkinson et al, ASCO, 2018
May 25, 2018 | Publication
A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
Mahalingam et al, Cancers, 2018
April 1, 2018 | Poster
Potentiating effect of reovirus in anti-PD1 therapy in colorectal cancer
Sanjay Goel et al, AACR, 2018
April 1, 2018 | Poster
Pelareorep promotes the expression of a chemokine signature that predicts response to immunotherapy
Grey Wilkinson et al, AACR, 2018
April 1, 2018 | Poster
B and T lymphocyte attenuator (BTLA) and PD-L1 significantly upregulated in reovirus treated TRAMP-C2 tumours
Pandha et al, IOVC, 2018

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch